Skip to Content

Year: 2022

Alzheimer’s drug slows progression of cognitive decline in clinical trial, drugmakers say

By Amanda Sealy, CNN A monoclonal antibody treatment for Alzheimer’s disease called lecanemab slows the progression of cognitive decline by 27% compared with a placebo, drugmakers Biogen and Eisai said Tuesday. The drug, tested in a Phase 3 global clinical trial, also met all secondary endpoints, showing “target engagement” with reduced amyloid levels — a

Continue Reading